Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 11 years
- Director since
- 2023
11 years of board service in total across 4 boards, counting each seat separately. Longest: Neurocrine Biosciences Inc., 3 years.
Neurocrine Biosciences Inc.
Director
Organon & Co.
Director
BeOne Medicines Ltd.
Director
Septerna Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Septerna Inc. June 26, 202685.3%
-
BeOne Medicines Ltd. June 11, 202697.2%
-
Organon & Co. June 9, 202696.8%
-
Organon & Co. June 10, 202597.4%
-
Neurocrine Biosciences Inc. May 21, 202592.7%
-
Organon & Co. June 4, 202498.7%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 11, 2026 | BeOne Medicines Ltd. | Grant or award | +18,980 | — | — |
| May 21, 2026 | Neurocrine Biosciences Inc. | Option exercise | +1,659 | — | — |
| May 22, 2025 | Neurocrine Biosciences Inc. | Option exercise | +1,435 | — | — |
| May 21, 2025 | BeOne Medicines Ltd. | Grant or award | +10,985 | — | — |
| Sep 30, 2024 | BeOne Medicines Ltd. | Grant or award | +8,151 | — | — |
| May 17, 2024 | Neurocrine Biosciences Inc. | Option exercise | +2,100 | — | — |
| May 17, 2024 | Neurocrine Biosciences Inc. | Open-market sale | −1,106 | $141.90 | $156,941 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.